Pauriah Maheshwar, Cismaru Gabriel, Sellal Jean-Marc, De Chillou Christian, Brembilla-Perrot Béatrice
CHU Nancy, Service de Cardiologie, Nancy, France.
J Electrocardiol. 2013 Nov-Dec;46(6):686-92. doi: 10.1016/j.jelectrocard.2012.12.019. Epub 2013 Jan 11.
We have studied the results of electrophysiological study (EPS) in patients with Wolff-Parkinson-White syndrome (WPW) and spontaneous adverse clinical presentation and determined whether isoproterenol added incremental value.
EPS was performed in 63 patients with WPW and adverse clinical presentation at baseline. EPS was repeated after infusion of isoproterenol in 37 patients, including 25 without criteria for a malignant form at baseline.
Atrioventricular orthodromic tachycardia was induced 44%, antidromic tachycardia in 11%, atrial fibrillation (AF) in 68% at baseline. At baseline EPS, criteria for a malignant form (AF induction and shortest CL <250 ms) were noted in 60%; tachycardia was not inducible in 16%. All the patients met the criteria for a malignant form after isoproterenol.
EPS at baseline missed 16% of patients at risk of life-threatening arrhythmias who had no inducible tachyarrhythmia and 40% without classical criteria for malignant form.
